Recent Publications by Cephalon: |
The phosphatidylinositol 3-kinase inhibitor LY 294002 inhibits GlyT1-mediated glycine uptake.
The actions of neurotransmitter glycine are regulated by the Na(+)/Cl(-)... | 16th July, 2008
| CNS Biology, Cephalon, Inc. 145 Brandywine Parkway, West Chester, PA
| Brain Res. 2008 Aug 28;1227:42-51. Epub 2008 Jun 28.
DOI Direct Link |
TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
Orally bioavailable, dual inhibitors of TIE-2/VEGF-R2 were identified by... | 9th July, 2008
| Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380-4245, USA.
| Bioorg Med Chem Lett. 2008 Apr 1;18(7):2368-72. Epub 2008 Mar 4.
DOI Direct Link |
Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
The histamine H3 receptor (H3R) modulates the release of neurotransmitters... | 17th June, 2008
| World Wide Discovery Research, CNS Biology, Cephalon, Inc., 145 Brandywine
| J Pharmacol Exp Ther. 2008 Jun;325(3):902-9. Epub 2008 Feb 27.
DOI Direct Link |
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Fused dihydroindazolopyrrolocarbazole oximes have been identified as low... | 10th June, 2008
| Department of Medicinal Chemistry, Cephalon, Inc., 145 Brandywine Parkway,
| Bioorg Med Chem Lett. 2008 Mar 15;18(6):1916-21. Epub 2008 Feb 7.
DOI Direct Link |
TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone.
An immobilized Staurosporine aglycone isostere where one of the indole... | 30th May, 2008
| Cephalon, Inc., Discovery Research, 145 Brandywine Parkway, West Chester,
| Bioorg Med Chem Lett. 2008 Jun 15;18(12):3551-5. Epub 2008 May 6.
DOI Direct Link |
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Selective inhibitors of TNF-alpha Converting Enzyme (TACE) based on... | 28th May, 2008
| Department of Discovery Chemistry and Discovery Biology, Bristol-Myers
| Bioorg Med Chem Lett. 2008 Jan 15;18(2):694-9. Epub 2007 Nov 21.
DOI Direct Link |
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
The ubiquitin-proteasome pathway plays a central role in regulation of the... | 20th May, 2008
| Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380,
| J Med Chem. 2008 Feb 28;51(4):1068-72. Epub 2008 Feb 5.
DOI Direct Link |
Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.
Novel ((2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamides were... | 20th May, 2008
| Departments of Discovery Chemistry and Discovery Biology, Bristol-Myers
| Bioorg Med Chem Lett. 2008 Mar 1;18(5):1577-82. Epub 2008 Jan 26.
DOI Direct Link |
Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects.
BACKGROUND AND OBJECTIVE: The fentanyl buccal tablet (FBT) is formulated... | 13th May, 2008
| Clinical Pharmacology, Cephalon Inc, Frazer, PA 19355, USA.
| Clin Drug Investig. 2008;28(1):1-7.
|
Fentanyl buccal tablet.
Studies of populations with chronic cancer pain have shown a high... | 26th April, 2008
| Cephalon, Inc., Frazer,
| Drugs Today (Barc). 2008 Jan;44(1):41-54.
DOI Direct Link |
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.
PURPOSE: Bendamustine has shown clinical activity in patients with disease... | 28th March, 2008
| Salmedix, acquired by Cephalon, Inc., Frazer, Pennsylvania, USA.
| Clin Cancer Res. 2008 Jan 1;14(1):309-17.
DOI Direct Link |
Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
BACKGROUND AND OBJECTIVE: Armodafinil, a wakefulness-promoting agent, is... | 19th March, 2008
| Clinical Pharmacology, Cephalon Inc, Frazer, PA 19355, USA.
| Clin Pharmacokinet. 2008;47(1):61-74.
|
A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
Many transgenic mouse models of Alzheimer's disease (AD) that deposit... | 7th December, 2007
| Department of CNS Biology, Discovery Research, Cephalon, Inc., 145
| Neurobiol Aging. 2007 Nov 27.
DOI Direct Link |
Modern Synthetic Methods & Chiral USA--a scientific update conference. Reaction to Reality. 11-13 July 2007, Philadelphia, PA, USA.
Many transgenic mouse models of Alzheimer''s disease (AD) that deposit... | 6th December, 2007
| Cephalon Inc, 383 Phoenixville Pike, PO Box 3005, Malvern, PA 19355, USA.
| IDrugs. 2007 Oct;10(10):703-5.
|
